Steve Riley
Pfizer (United States)(US)
Publications by Year
Research Areas
Cardiac electrophysiology and arrhythmias, Amyloidosis: Diagnosis, Treatment, Outcomes, Pharmacogenetics and Drug Metabolism, Pharmaceutical studies and practices, Pharmacology and Obesity Treatment
Most-Cited Works
- → Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy(2018)2,603 cited
- → Scientific white paper on concentration-QTc modeling(2017)250 cited
- → Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial ( ATTR‐ACT ) and long‐term extension study(2020)204 cited
- → Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance(2013)183 cited
- → Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis(2016)180 cited
- → Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase(2015)177 cited
- → The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”(2013)99 cited
- → Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)(2017)83 cited
- → Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward(2014)61 cited
- → Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story(2021)55 cited